factual
FDA Steered Researchers Toward Depression
The expansion of psychedelic research into depression came from the FDA itself: when Hopkins and NYU researchers sought approval for a phase 3 study of anxiety and depression in cancer patients, FDA regulators noted a strong signal for depression generally and, given the enormous unmet need and limited tools, encouraged studying depression in a larger population—major depression in America and treatment-resistant depression in Europe.
factualpending
Speaker
Michael PollanEvidence Quote
“when they when the researchers from hopkins and nyu brought the results of these phase 2 trials to their meeting at the fda they were hoping to get approval to do a phase 3 study of the same thing um depression and anxiety in cancer patients but it was the regulators at the fda... they said you know there's a strong signal here”
Created: 6/14/2026, 2:36:43 AM
Your notes
Loading notes...